Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
Rank in Stocks
#2196
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Share Price
$3.40
Market Cap
$9.07B
Change (1 day)
-1.61%
Change (1 year)
-16.08%
Country
CN
Trade Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Category
Healthcare
P/S ratio for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
P/S ratio as of October 2026 TTM: 1.42
According to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.42. At the end of 2024 the company had a P/S ratio of 1.61.
P/S ratio history for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from 2001 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.42 | -15.85% |
| 2025 | 1.69 | 4.80% |
| 2024 | 1.61 | 0.10% |
| 2023 | 1.61 | -22.99% |
| 2022 | 2.09 | -34.98% |
| 2021 | 3.22 | -29.58% |
| 2020 | 4.57 | 91.44% |
| 2019 | 2.38 | 9.32% |
| 2018 | 2.18 | -63.06% |
| 2017 | 5.91 | 61.09% |
| 2016 | 3.67 | -14.40% |
| 2015 | 4.28 | 6.40% |
| 2014 | 4.03 | -7.88% |
| 2013 | 4.37 | 57.04% |
| 2012 | 2.78 | 10.47% |
| 2011 | 2.52 | -54.62% |
| 2010 | 5.55 | -11.49% |
| 2009 | 6.27 | 80.89% |
| 2008 | 3.47 | -32.97% |
| 2007 | 5.17 | 295.14% |
| 2006 | 1.31 | -8.44% |
| 2005 | 1.43 | -21.64% |
| 2004 | 1.82 | -11.63% |
| 2003 | 2.06 | -48.23% |
| 2002 | 3.99 | -43.85% |
| 2001 | 7.10 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 2.19 | 53.77% |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 396.29% |
IN
|
